Date & Time of Session - 3/3/26 - from 12:00 - 1:00PM
Overview
Catatonia is a potentially life-threatening yet highly treatable neuropsychiatric syndrome that remains underrecognized across medical and psychiatric settings. Catatonia cases are increasing in both adult and pediatric populations, yet treatment decisions are often based on limited evidence. Many clinicians are unfamiliar with catatonia and associated medications. Pharmacists are uniquely positioned to identify medication-induced causes, optimize benzodiazepine therapy, help mitigate adverse effects, and guide safe and effective use of electroconvulsive therapy.
Objectives
Upon completion of this activity, participants will be able to:
1. Describe the pathophysiology and presentation of catatonia
2. List recommended pharmacologic agents for catatonia treatment and electroconvulsive therapy
3. Discuss considerations when treating catatonia in special populations
4. Provide recommendations regarding catatonia management when provided a patient case
Target Audience
Pharmacists, residents, and students
Special Services
If you require special assistance to attend this event, please call Megan Russell at (304) 550-0896.
Speaker:
Angela Giglione, PharmD
PGY2 Pediatric Pharmacy Resident
UK College of Pharmacy - Lexington, Kentucky
- 1.00 ACPE
In support of improving patient care, UK HealthCare CECentral is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), the American Nurses Credentialing Center (ANCC), and the Association of Social Work Boards (ASWB) to provide continuing education for the healthcare team.
This knowledge-based activity will award 1.00 contact hour(s) (0.100 CEUs) of continuing pharmacy education credit in states that recognize ACPE providers. Course JA-UAN Number: JA0000312-0000-25-046-L01-P
- 1.00 ParticipationUK Healthcare CECentral certifies this activity for 1.00 hour(s) of participation.

Facebook
X
LinkedIn
Forward